c-Kit (D820E)

KIT · Variant type: point · HGVS: p.D820E

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Pacritinib	99.0%	1.0%	88.64
2	Avapritinib	99.0%	1.0%	97.73
3	Tivozanib	98.9%	1.1%	92.42
4	Dasatinib	98.8%	1.2%	87.97
5	Nintedanib	98.7%	1.3%	90.23
6	Ripretinib	98.6%	1.4%	92.95
7	Ponatinib	98.1%	1.9%	78.23
8	Axitinib	97.9%	2.1%	93.23
9	Pralsetinib	97.8%	2.2%	93.43
10	Erdafitinib	96.5%	3.5%	95.71
11	Apatinib	96.3%	3.7%	97.73
12	Lenvatinib	95.6%	4.4%	97.74
13	Cabozantinib	95.3%	4.7%	92.73
14	Selpercatinib	95.0%	5.0%	96.72
15	Brigatinib	94.5%	5.5%	82.96
16	Fostamatinib	94.1%	5.9%	96.74
17	Sorafenib	93.4%	6.6%	96.72
18	Quizartinib	93.0%	7.0%	99.50
19	Nilotinib	92.7%	7.3%	96.49
20	Regorafenib	92.5%	7.5%	95.99
21	Sunitinib	92.5%	7.5%	91.73
22	Pazopanib	92.4%	7.6%	97.49
23	Imatinib	90.7%	9.3%	99.00
24	Vemurafenib	90.3%	9.7%	96.49
25	Pexidartinib	87.9%	12.1%	99.49

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Pacritinib	99.0%	—	—
Avapritinib	99.0%	—	—
Tivozanib	98.9%	—	—
Dasatinib	98.8%	—	—
Nintedanib	98.7%	—	—
Ripretinib	98.6%	—	—
Ponatinib	98.1%	—	—
Axitinib	97.9%	—	—
Pralsetinib	97.8%	—	—
Erdafitinib	96.5%	—	—
Apatinib	96.3%	—	—
Lenvatinib	95.6%	—	—
Cabozantinib	95.3%	—	—
Selpercatinib	95.0%	—	—
Brigatinib	94.5%	—	—
Fostamatinib	94.1%	—	—
Sorafenib	93.4%	—	—
Quizartinib	93.0%	—	—
Nilotinib	92.7%	—	—
Regorafenib	92.5%	—	—
Sunitinib	92.5%	—	—
Pazopanib	92.4%	—	—
Imatinib	90.7%	—	—
Vemurafenib	90.3%	—	—
Pexidartinib	87.9%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 19.8ms